Capmatinib HCl INN
Composition: Each film coated tablet contains Capmatinib 200mg as Capmatinib HCl INN.
Indications:
It is indicated for the treatment of adult patients with
metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that
leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected
by an FDA approved test.
Dosage
& administration: The recommended
dosage of Capnib-200 is 400mg orally twice daily with or without food. Swallow
the tablets whole. Do not break, crush or chew the tablets. If a patient misses
or vomits a dose, instruct the patient not to make up the dose, but to take the
next dose at its scheduled time. Or, as directed by the registered physicians.
Use in
pregnancy & lactation: It can cause fetal
harm when administered to a pregnant woman. There are no available data on
Capnib-200 use in pregnant women. Lactation: There are no data on the
presence of Capmatinib or its metabolites in either human or animal milk or its
effects on the breastfed child or on milk production.
Packing: Each box contains 56 tablets in a container.
